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May 20, 2008

HAND DELIVERED

Michele Lumbert, Clerk
Kennebec County Superior Court
95 State Street
Augusta, ME 04330
Re:

State of Maine v. Merck 8c Co.
Civil Docket No. CV-08-

Dear Ms. Lumbert:
Enclosed for filing please find a Complaint, Summary Sheet and
Consent Judgment. Please bring this matter to the Court’s attention at
your earliest convenience.
If you have any questions, please feel free to call me at 626-8591.

LJC/sm
Enclosure
cc:

Nicolas Gess, Esq.
Brian R Baggetta, Esq.

PRINTED ON RECYCLED PAPER

This summary sheet and the information contained herein neither replace nor supplement the tiling and service of pleadings or other papers as
required by the Maine Rules o f Court or by law. This form is required for the use of the Clerk of Court for the purpose of initiating or
updating the civil docket. (SEE INSTRUCTIONS ON REVERSE)________________________________________________________________
C o u n t y o f F i l i n g or D i s t r i c t C o u r t J u r i s di c t i on : KENNEBEC

I.

II. CAUSE OF ACTION

(Cite the primary civil statutes under which you are filing, if any.) Pro se plaintiffs:

If unsure, leave blank.

Maine's Unfair Trade Practices Act (UTPA) 5 M.R.S.A. § 207 and 209.
III.

IV.
V.

□
□
□
□
□
□
□
□
□
□
□
□

NATURE OF FILING
[*7] Initial Complaint
1 | Third-Party Complaint
1 | Cross-Claim or Counterclaim
| | If R e i n s t a t e d or R e o p e n e d c a s e , gi ve or i g i na l D o c k e t N u m b e r
(If filing a second or subsequent Money Judgment Disclosure, give docket number of first disclosure)
□

•.

TITLE TO REAL ESTATE IS INVOLVED

MOST DEFINITIVE NATURE OF ACTION. (Place an X in one box only )

Pro se plaintiffs:

GENERAL CIVIL (CV)
Contract
□
Contract
□
□
Declaratory/ Equi tabl e Re l i e f
□
General Injunctive Relief
□
□
Declaratory Judgment
□
□
Other Equitable Relief
□
□
C o n st i t u t i o n a l / C i v i l R i g h ts
□
Constitutional/Civil Rights
□
□
Stat utory Actions
□
E l Unfair Trade Practices
□
Freedom of Access
□
□
Other Statutory Actions
□
□
M i s ce l l an e o u s Civil
□
Drug Forfeitures
□
□
CHILD PROTECTIVE CUSTODY (PC)

Personal Injury Tort
Property Negligence
Auto Negligence
Medical Malpractice
Product Liability
Assault/Battery
Domestic Torts
Other Negligence
Other Personal Injury Tort
Non-Personal Injury Tort
Libel/Defamation
Auto Negligence
Other Negligence
Other Non-Personal Injury Tort

If unsure, leave blank.

Other Forfeitures/Property Libels
Land Use Enforcement (80K)
Administrative Warrant
HIV Testing
Arbitration Awards
Appointment of Receiver
Shareholders' Derivative Actions
Foreign Deposition
Pre-action Discovery
Common Law Habeas Corpus
Prisoner Transfers
Foreign Judgments
Minor Settlements
Other Civil

1 1 Non-DHS Protective Custody
SPECIAL ACTIONS (SA)
□

Money Judgment
Money Judgment Request Disclosure

Title Actions
1 1 Quiet Title
1 1 Eminent Domain
□ Easements
□ Boundaries
□
VI.
□

Governmental Body (80B)

REAL ESTATE (RE)
Foreclosure
Mise. Real Estate
Foreclosure for Non-pmt (ADR exempt)
Equitable Remedies
□
□
Foreclosure
Other
Mechanics Lien
□
□
Partition
T respass
□
Trespass
Adverse Possession
□
□
APPEALS ÍAP) (To be filed in Superior Co urt) (ADR exem pt)
Administrative Agency (80C)
Other Appeals
□
□

1 1 Nuisance
| | Abandoned Roads
| | Other Real Estate

M . R . C i v . P . 16B A l t e r n a t i v e D i s p u t e R e s o l u t i o n ( ADR ) :
I certify that pursuant to M.R.Civ.P. 16B(b), this case is exempt from a required ADR process because:
□
It falls within an exemption listed above (i.e., an appeal or an action for non-payment of a note in a secured transaction).
□
The plaintiff or defendant is incarcerated in a local, state or federal facility.
□
The parties have participated in a statutory prelitigation screening process w ith____________________________________
(name o f neutral) o n _____________________________________ (date).
□
The parties have participated in a formal ADR process with ________________________________________ (name of neutral)
o n _____________________________________ (date).
□
This is a Personal Injury action in which the plaintiffs likely damages will not exceed $30,000, and the plaintiff requests an
exemption from ADR.

CV-001 Rev 01107

| VII. ( a ) Q PLAINTIFFS (Name & Address i ncluding county)
or □ Third-Party, □ Counterclaim or Cross-Clai m Plaintiffs
□ The plaintiff is a prisoner in a local, state or federal facility.

STATE OF MAINE

(b) Attorneys (Name, Bar number, Firm name, Address, Telephone Number) If all counsel listed do NOT represent all plaintiffs,
( I f p r o se pl ai nti ff, leaTe blank)
specify who the listed attorney(s) represent.

Linda J. Conti, Bar No. 3638
Assistant Attorney General
Office of the Attorney General
6 State House Station
Augusta ME 04333-0006
(207) 626-8591
VIII. (a)(7) DEFENDANTS (Name & Address including county)
and/or Q Third-Party, Q Counterclaim or Q] Cross-Claim Defendants
□ The defendant is a prisoner in a local, state or federal facility,

Merck & Co., Inc.
One Merck Drive
Whitehouse Station, New Jersey

(b) Attorneys (Name, Bar number, Firm name, Address, Telephone Number)
(Ifknown)

If all counsel listed do NOT represent all
d e f e n d a n t s , sp e c i fy wh o the listed a t t or n e y ( s )

Nicholas M. Gess, Esq., ME Bar NO. 0 0 2 5 0 4
Bingham McCutchen LLP
2020 K Street, NW
Washington DC 20006-1806

represent.

IX.

RELATED CASE(S) IF ANY
Assigned Judge/Justice

Date:

Docket Number

<£
Name ofLead Attorney o f Record or Pro se Party

Signature o f Attome^/or Pro se Party

c:

SUPERIOR COURT
CIVIL ACTION
DOCKET NO. CV-08-

STATE OF MAINE
KENNEBEC, SS.

STATE OF MAINE,
Plaintiff,
COMPLAINT

V.

MERCK & CO., INC.,
Defendant.

This complaint alleges claims for relief based upon violation o f Maine’ s Unfair Trade
Practices Act (U T P A ), 5 M .R.S.A . §207 and 209. Plaintiff, State o f Maine for its Complaint
alleges that all times material herein:

JURISDICTION

1.

This Court has jurisdiction over defendant and this matter pursuant to 4 M.R.S.A. §105
and M .R.S.A. § 209.

PARTIES

2.

Plaintiff, State o f Maine, brings this action by and through Attorney General G. Steven
Rowe, pursuant to 5 M .R.S.A . §§ 191 and 209 and the powers vested in him by common
law.

3.

Defendant Merck is incorporated under the laws and statutes o f the State o f N ew Jersey;
its principal place o f business is One Merck Drive, Whitehouse Station, N ew Jersey. At
all times material to this complaint, Defendant transacted business in the State o f Maine
by advertising, soliciting, selling, promoting and distributing prescription drugs,
including V iox x® , to consumers in the State o f Maine.

BACKGROUND
4

.

V ioxx is a type o f non-steroidal anti-inflammatory drug (“ N S A ID ” ) commonly known as
a “ selective COX-2 inhibitor” or “ COX-2.” N S A ID s are widely prescribed to treat the
symptoms o f arthritis as w ell as chronic and acute pain from other causes. N SAID s are

highly effective against pain and inflammation; however, they can cause gastro intestinal
(G I) side effects, including serious adverse events such as obstructions, bleeds, and
perforations.
5.

N SAID s work against pain and inflammation by inhibiting enzymes known as cyclo
oxygenase or COX. There are two forms o f C O X enzymes: C O X - 1 and COX-2. CO X1 is involved in the maintenance and repair o f the GI system as well as the production o f
thromboxane, a substance that promotes blood clots. In addition to its role in pain and
inflammation, COX-2 is involved in the production o f prostacyclin, a substance that helps
prevent blood clots. For cardiovascular health, prostacyclin and thromboxane must be in
balance.

6.

Selective COX-2 inhibitors are N S A ID S that block COX-2 without affecting COX-1.
This class o f drugs was developed in the 1990s in hope o f treating pain and inflammation
without blocking C O X - l’ s beneficial effect on the GI system. Unfortunately, it turned out
that COX-2 drugs create an imbalance between thromboxane and prostacyclin that result
in an increased risk o f heart attack and other adverse cardiovascular events. Any
advantage C O X -2’ s have regarding GI safety is offset by increased cardiovascular risk.

DEFENDANTS COURSE OF CONDUCT
7.

Merck’ s conduct described in this Complaint was intentional within the meaning o f 5
M.R.S.A. § 209.

8.

Merck began marketing V iox x in M ay o f 1999 with an aggressive and deceptive
promotional campaign directed at both consumers and at health care professionals.

9

When promoting V ioxx directly to consumers and to health care professionals, Merck
misrepresented the cardiovascular safety o f Vioxx.

10.

On September 30, 2004, Merck finally admitted that V iox x caused serious cardiovascular
adverse events and withdrew the drug from the market.

2

11.

For the entire period o f time V ioxx was on the market, M erck’ s advertisements and
promotional activities misrepresented V ioxx’ s cardiovascular safety.

CAUSE OF ACTION
12.

The allegations contained in paragraphs 1-11 are incorporated herein by reference.

13.

Defendant Merck violated 5 M .R.S.A. §207 by misrepresenting that Vioxx had
characteristics, uses, benefits, and qualities that it does not have.

PRAYER FOR RELIEF
W HEREFORE, the plaintiff prays that this honorable Court enter an Order:
A.

Issuing a permanent injunction prohibiting the defendant, its agents,
employees, and all other persons and entities, corporate or otherwise, in
active concert or participation with any o f them, from engaging in unfair
or deceptive conduct.

B.

Ordering the defendant to pay all costs for the prosecution and
investigation o f this action;

C.

Ordering defendant to pay civil penalties o f $10,000 for each and
every violation o f 5 M.R.S.A. §207; and

D.

Granting such other and further relief as the Court deems equitable and
proper.

Dated

M ay 20, 2008
Respectfully submitted,
G. STE V E N R O W E
Attorney General

S\

£/

X
iu-

/Orth

Linda J/C,6ntp
AssistanfAttorney General
Maine Bar Registration No. 3638
Office o f Attorney General
6 State House Station
Augusta M E 04333-0006
Tel: (207) 626-8591
Attorneys for Plaintiff, State o f Maine
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STATE OF MAINE
KENNEBEC, SS.

SUPERIOR COURT
CIVIL ACTION
_
DOCKET NO. CV-08- I t -f

STATE OF MAINE,
Plaintiff,
CONSENT JUDGMENT

v.
MERCK & CO., INC.,
Defendant.

The parties voluntarily enter into this Consent Judgment on the terms
and conditions set forth below:

Definitions:
a.

“Covered Conduct” shall mean Merck’s promotional and

marketing practices regarding the prescription drug Vioxx®, as well as Merck’s
practices related to Data Safety Monitoring Boards, publication of clinical
trials, and the support of continuing medical education that were the subject
of an investigation by the Signatory Attorneys General under the State
Consumer Protection Laws. “Covered Conduct” shall not include conduct
relating to promotion and marketing of the prescription drugs Vytorin® and/or
Zetia® and to publication of clinical trials, practices related to Data Safety
Monitoring Boards, and the support of continuing medical education, relating
to Vytorin® and/or Zetia®.
b.

“Effective Date” shall mean the date by which all Parties have

executed the Consent Judgment.

c.

“FDA Amendments Act of 2007” (or “FDA Amendments Act” or

“the Act”) shall mean Public Law No. 110-85, which among other things,
creates a federal clinical trial registry and results data bank.
d.

“FDA’s Guidances for Industry” shall mean documents published

by the United States Department of Health and Human Services, Food and
Drug Administration (FDA), that represent the FDA’s current
recommendations on a topic.
e.

“Individual States” and “State” shall mean each Signatory

Attorney General who is participating in the Multistate Working Group.
f.

“Joint Venture(s)” shall mean any entity in which Merck

maintains a direct and/or indirect ownership interest of 50% or less on the
date this Agreement is signed.
g.

“Merck” shall mean Merck & Co., Inc. and its United States-based

affiliates, subsidiaries, predecessors, successors, and assigns, but shall not
include any Joint Ventures (as that term is defined in the prior subparagraph).
h.

“Multistate Executive Committee” shall mean the Attorneys

General and their staffs representing Arizona, California, Florida, Illinois, Ohio,
Oregon, Pennsylvania, Texas, and Vermont.
i.

“Multistate Working Group” (“MSWG”) shall mean the Attorneys

General and their staffs representing, Arizona, Arkansas, California,
Connecticut, Florida, District of Columbia, Hawaii, Idaho, Illinois, Iowa,
Kansas, Maine, Maryland, Massachusetts, Michigan, Nebraska, Nevada, New
2

Jersey, North Carolina, North Dakota, Ohio, Oregon, Pennsylvania, South
Carolina, South Dakota, Tennessee, Texas, Vermont, Washington, and
Wisconsin.
j.

“Parties” shall mean Merck and the Individual States.

k.

“Product” shall mean any prescription drug or biological product

manufactured, distributed, sold, marketed or promoted in the United States in
any way.
l.

“Signatory Attomey(s) General” shall mean the Attorney General,

or his or her designee, of each state in the Multistate Working Group.
m.

“State Consumer Protection Laws” shall mean the consumer

protection laws under which the Signatory Attorneys General have conducted
their investigation.1

1 The States’ consumer protection statutes are: A R IZ O N A - Consumer Fraud Act, A.R.S. § 441521, et seq .; A R K A N S A S - Ark. Code Ann. § 4-88-101, et seq., C A L IF O R N IA - Bus. & Prof.
Code, §§ 17200 et seq., and 17500 et seq.; C O N N E C T IC U T - Conn. Gen. Stat., §§ 42-110a et
seq:, D IS T R IC T OF C O L U M B IA - Consumer Protection Procedures Act, D.C. Code § 28-3901,
et seq:, H A W A II- Uniform Deceptive Trade Practice Act, Haw. Rev. Stat. Chpt. 481A and Haw.
Rev. Stat. § 480-2.; F L O R ID A - Deceptive and Unfair Trade Practices Act, Fla. Stat. Ch.
501.201 et seq:, ID A H O - Consumer Protection Act, Idaho Code Section 48-601 et seq:,
IL L IN O IS - Consumer Fraud and Deceptive Business Practices Act, 815 ILCS § 505/1 et seq.
(2006 State Bar Edition); IO W A - Iowa Consumer Fraud Act, Iowa Code Section 714.16;
K A N S A S - Consumer Protection Act, K .S.A. 50-623 et seq:, M A IN E - Unfair Trade Practices
Act, 5 M .R.S.A. § 207 et seq:, M A R Y L A N D - Consumer Protection Act, Md. Code Ann., Com.
Law § 13-101 et seq:, M A S S A C H U S E T T S - Consumer Protection Act, M .G.L. c. 93A et seq:,
M IC H IG A N - Michigan Consumer Protection Act, M C L 445.901 et seq:, N E B R A S K A Consumer Protection Act, NRS §§ 59-1601 et seq. and Uniform Deceptive Trade Practices Act,
NRS §§ 87-301 et seq:, N E W JERSEY - New Jersey Consumer Fraud Act, 56:8-1 et seq:,
N E V A D A - Deceptive Trade Practices Act, Nevada Revised Statutes 598.0903 et seg.;NORTH
C A R O L IN A - Unfair and Deceptive Trade Practices Act, N.C. Gen. Stat. § 75-1.1 et seq:,
N O R T H D A K O T A -Unlawful Sales or Advertising Practices, N.D. Cent. Code. § 51-15-02 et
secy, OHIO- Consumer Sales Practices Act, R.C. 1345.01, et seq:, O R E G O N - Unlawful Trade
Practices Act, ORS 646.605 to 646.656; P E N N S Y L V A N IA - Unfair Trade Practices and
Consumer Protection Law, 73 P.S. § 201-1 et seq:, SOU TH C A R O L IN A - Unfair Trade

3

n.

“Vioxx®” shall mean rofeeoxib.
1.

The parties have agreed to resolve the issues raised by the Covered
Conduct by entering into this Consent Judgment (hereinafter “Judgment”).
(a)

Merck is entering into this Judgment solely for the purpose of

settlement, and nothing contained herein may be taken as or construed to be
an admission or concession of any violation of law, rule, or regulation, or of
any other matter of fact or law, or of any liability or wrongdoing, all of which
Merck expressly denies. Merck does not admit any violation of the State
Consumer Protection Laws set forth in footnote 1, and does not admit any
wrongdoing that was or could have been alleged by any Attorney General
before the date of the Judgment under those laws. No part of this Judgment,
including its statements and commitments, shall constitute evidence of any
liability, fault, or wrongdoing by Merck.
(b)

This Judgment shall not be construed or used as a waiver or

limitation of any defense otherwise available to Merck in any action, or of
Merck’s right to defend itself from, or make any arguments in, any private
individual or class claims or suits relating to the subject matter or terms of
Practices Act, S. C. CODE. A N N . Sections 39-5-10, et seq.; SO U TH D A K O T A - Deceptive
Trade Practices Act, S.D. Codified Laws § 37-24, et seq.; TENNESSEE-Tennessee - Consumer
Protection Act, Tenn. Code Ann. §§ 47-18-101 et seq.; T E X A S - Deceptive Trade Practices Consumer Protection Act, Tex. Bus. and Com. Code § 17.47, et seq.; V E R M O N T - Consumer
Fraud Act, 9 V.S.A. § 2451 et seq.; W A S H IN G T O N - Unfair Business Practices/Consumer
Protection Act, R.C.W. 19.86 et seq.; W IS C O N S IN - Wis. Stat. § 100.18 (Fraudulent
Representations).

4

this Judgment. This Judgment is made without trial or adjudication of any
issue of fact or law or finding of liability of any kind.
(c)

It is the intent of the Parties that this Judgment not be

admissible in other cases or binding on Merck in any respect other than in
connection with the enforcement of this Judgment.
(d)

No part of this Judgment shall create a private cause of action or

confer any right to any third party for violation of any federal or state statute
except that a State may file an action to enforce the terms of this Judgment.
(e)

All obligations undertaken by Merck in this Judgment shall apply

prospectively, except to the extent permitted by the National Library of
Medicine, Merck shall submit, as soon as practicable, clinical trial results to
the clinical trial registry and results data bank created by the FDA
Amendments Act for all “applicable clinical trials” (as that term is defined by
the Act) of FDA-approved Merck Products that were initiated after July 1,
2005.
2.

Merck shall register clinical trials and submit results to the registry and
results data bank as required by the FDA Amendments Act and any
accompanying regulations that may be promulgated pursuant to that Act.
3.
Merck shall not make any written or oral claim that is false, misleading
or deceptive regarding any FDA-approved Merck Product.
4.
5

Merck shall not make any written or oral promotional claims of safety or
effectiveness for any FDA-approved Merck Product in a manner that violates
the Food, Drug and Cosmetic Act, 21 U.S.C. § 301 et seq. (“FDCA”),
accompanying regulations, or voluntary agreements with FDA, as interpreted
by the FDA in a writing by the Director of the Center for Drug Evaluation at the
FDA.
5.
A written or oral claim made by Merck in connection with a Joint
Venture Product which written or oral claim has not been approved by the
Joint Venture shall be subject to the provisions of Paragraphs 3 and 4. In no
event, however, shall Paragraphs 3 and 4 apply to Vytorin® or Zetia®.
6.
Nothing in this Judgment shall require Merck to:
i.

take an action that is prohibited by the FDCA or any

regulation promulgated thereunder, or by FDA; or
ii.

fail to take an action that is required by the FDCA or any

regulation promulgated thereunder, or by FDA. Any written or oral promotional
claim subject to this Judgment which is the same, or materially the same, as
the language required or agreed to by the Director of DDMAC or the Director of
the Center for Drug Evaluation or their authorized designees in writing shall
not constitute a violation of this Judgment.
7.

6

Merck agrees to delay direct to consumer (“DTC”) television advertising
for any Merck Product indicated for pain relief immediately following such
Product’s approval by the FDA, if the Director of the Center for Drug Evaluation
at FDA recommends such a delay in writing to Merck. Merck’s delay would be
for the same period as recommended by the Director of the Center for Drug
Evaluation at FDA.
8.
Merck agrees to submit all new DTC television advertising campaigns
for any Merck Product to FDA for pre-review, wait until Merck receives a
response from FDA prior to running the advertising campaign, and to modify
such advertising consistent with any written comments received from FDA.
9.
Merck’s obligations with respect to Paragraph 7 shall remain in effect for
ten years following the Effective Date. Merck’s obligations with respect to
Paragraph 8 shall remain in effect for seven years following the Effective Date.
With respect to Paragraph 7, Merck shall abide by any such written
recommendation as long as the submission of the TV advertising campaign is
made within ten years following the Effective Date. With respect to Paragraph
8, Merck shall abide by any such written recommendation when such
submission is made within seven years of the Effective Date.
10.

When presenting information in detailing pieces, brochures, booklets,
mailing pieces, published journals, magazines, other periodicals and
7

newspapers, and broadcast through media such as radio, television, the
Internet, and telephone communications systems, about a Clinical Study that
relates to an FDA-approved Merck Product, Merck shall (1) accurately reflect
the methodology used to conduct the Clinical Study; (2) shall not present
favorable information or conclusions from a study that is inadequate in design,
scope, or conduct to furnish significant support for such information or
conclusions; and (3) shall not use statistical analyses and techniques on a
retrospective basis to discover and cite findings not soundly supported by the
study, or to suggest scientific validity and rigor for data from studies the design
or protocol of which are not amenable to formal statistical evaluations.
11.

When presenting information in detailing pieces, brochures, booklets,
mailing pieces, published journals, magazines, other periodicals and
newspapers, and broadcast through media such as radio, television, the
Internet, and telephone communications systems, about a Clinical Study or
analysis of Clinical Studies as evidence of an FDA-approved Merck Product’s
safety, Merck shall not (1) present information from a study in a way that
implies that the study represents larger or more general experience with the
drug than it actually does; nor (2) use statistics on numbers of patients, or
counts of favorable results or side effects, derived from pooling data from
various insignificant or dissimilar studies in a way that suggests either that
such statistics are valid if they are not or that they are derived from large or
significant studies supporting favorable conclusions when such is not the case.
8

12.

When presenting information in detailing pieces, brochures, booklets,
mailing pieces, published journals, magazines, other periodicals and
newspapers, and broadcast through media such as radio, television, the
Internet, and telephone communications systems, about a Clinical Study or
analysis of Clinical Studies as evidence of an FDA-approved Merck Product’s
safety, Merck shall not (1) present favorable information or conclusions from a
study that is inadequate in design, scope, or conduct to furnish significant
support for such information or conclusions; (2) use the concept of statistical
significance to support a claim that has not been demonstrated to have clinical
significance or validity, or fails to reveal the range of variations around the
quoted average results; nor (3) use statistical analyses and techniques on a
retrospective basis to discover and cite findings not soundly supported by the
study, or to suggest scientific validity and rigor for data from studies the design
or protocol of which are not amenable to formal statistical evaluation.
13.
(a)

Merck shall comply with the ACCME Standards for Commercial

Support, a copy of which is attached hereto as Appendix 1.
(b)

Any person who acts in a promotional capacity for Merck with

respect to an FDA approved Merck Product shall be obligated under his or her
contract with Merck, as a condition for any future promotional relationship
with Merck, to disclose to CME participants orally and to the CME provider for
inclusion in the written materials the existence, nature and purpose of his or
9

her arrangement with Merck when speaking at a CME program if: (i) the
Product the speaker promoted for Merck is in the same therapeutic category as
the subject of the CME program, and fii) the CME program occurs within 12
months of the speaker performing work for or receiving compensation from
Merck. Such disclosure shall set forth the type of promotional work engaged in
by the speaker and the name of the therapeutic category with respect to which
such promotion was performed.
(c)

Merck shall not provide funding for CME when Merck has

knowledge at the time the decision to fund the CME is made that a speaker at
the CME has also been a promotional speaker in the past 12 months at a
Merck-sponsored promotional event related to the class of drugs to be
discussed in the CME.
14.
Merck’s obligations with respect to CME shall remain in effect for 9
years following the Effective Date. Merck’s obligations with respect to
Paragraph 13(b) shall only apply to speakers’ contracts entered into, amended
to extend the contract period, or renewed after the date of this Agreement.
15.
All members of any external Data Safety Monitoring Board (“DSMB”)
constituted by Merck after the Effective Date for a Merck-Sponsored
Clinical Trial shall be prohibited from:
(a)

holding more than $25,000 of Merck stock (exclusive of mutual

fund holdings) at the time of DSMB membership;
10

(b)

trading in Merck stock during their DSMB service;

(c)

serving as a clinical trial investigator in the trial being monitored

by the DSMB; and
(d)

consulting for, being employed by, or entering into any future

consulting or employment relationships with, Merck while serving on the
DSMB, except that DSMB members may (i) concurrently serve on other
DSMBs for Merck, and/or (ii) consult for Merck Research Laboratories where
the annual aggregate compensation for such non-promotional consulting
services does not exceed $15,000.
16.
Merck’s obligations with respect to DSMB membership set forth in
Paragraph 15 shall remain in effect for DSMBs constituted within 7 years
following the Effective Date.
17.
Merck agrees to enhance further its process for reviewing potential
conflicts of interest such that all members of a DSMB shall, prior to service
thereon, complete a “competing interests” form which shall include questions
regarding consulting arrangements or frequent speaking arrangements with
the sponsor; career involvement with a product or technique under study;
hands-on participation in the trial; emotional involvement in the trial;
intellectual conflicts; involvement in regulatory issues relevant to trial
procedures; investment in competing products; and involvement in the
publication. The forms shall carry a continued updating obligation and shall be
11

forwarded to, and reviewed by, the DSMB chair who, in turn, will forward them
to the study’s Steering Committee chair or other appropriate individual for

review and action, as needed, in advance of the first DSMB meeting and on an
ongoing basis.
18.
Merck shall require all individuals who are named as authors on a
Merck-sponsored manuscript reporting the results of a Merck-sponsored study
to fulfill the following conditions: (a) the individual shall have made substantial
contribution to the conception and design, or acquisition of data, or analysis
and interpretation of data; (b) the individual shall have been involved in
drafting the article or revising it critically for important intellectual content;
and (c] the individual shall have final approval rights of the version to be
published.
19.
When a large, multi-center group has conducted the research, the
manuscript should identify the individuals who accept direct responsibility for
the manuscript. These individuals should fully meet the criteria for authorship
defined in Paragraph 18 above.
20.

By its execution of this Judgment, State of Maine releases Merck and all
of its past and present subsidiaries, affiliates, predecessors and successors
(collectively, the “Released Parties”) from the following: all civil claims, causes
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of action, damages, restitution, fines, costs, and penalties on behalf of the State
of Maine under the above-cited consumer protection statutes arising from the
Covered Conduct that is the subject of this Judgment.

21.

Notwithstanding any term of this Judgment, specifically reserved and
excluded from the Release in Paragraph 20 as to any entity or person,
including Released Parties, are any and all of the following:
a.

Any criminal liability that any person or entity, including Released

Parties, has or may have to the State of Maine.
b.

Any civil or administrative liability that any person or entity,

including Released Parties, has or may have to the State of Maine under any
statute, regulation or rule not expressly covered by the release in Paragraph
20 above, including but not limited to any and all of the following claims:
i)

State or federal antitrust violations:

ii)

Reporting practices, including “best price”, “average

wholesale price” or “wholesale acquisition cost;”
iii)

Medicaid violations, including federal Medicaid drug rebate

statute violations, Medicaid fraud or abuse, and/or kickback violations
related to any State’s Medicaid program; and,
iv)
c.

State false claims violations.
Any liability under the State of Maine’s above-cited consumer

protection laws which any person or entity, including Released Parties, has or
13

may have to individual consumers or State program payors of said State, and
which have not been specifically enumerated as included herein.
d.

Any liability for failure to comply with Maine’s Prescription Drug

Clinical Trial Reporting Rule: DHHS Rule 10-144 ch. 275 AG Rule 26-0259 Ch.
I l l with respect to any drug other than Vioxx.
22 .
Within ten (10) days of the Effective Date of this Judgment, Merck shall
pay a total amount of fifty eight million dollars ($58,000,000) to be divided and
paid by Merck directly to each Signatory Attorney General in an amount to be
designated by and in the sole discretion of the Multistate Executive Committee.
Said payment shall be used by the States for attorneys’ fees and other costs of
investigation and litigation, or to be placed in, or applied to, the consumer
protection enforcement fund, consumer education, litigation or local consumer
aid fund or revolving fund, used to defray the costs of the inquiry leading
hereto, or for other uses permitted by state law, at the sole discretion of each
Signatory Attorney General.
23.
For the purposes of resolving disputes with respect to compliance with
this Judgment, should any of the Signatory Attorneys General have a
reasonable basis to believe that Merck has engaged in a practice that violates a
provision of this Judgment subsequent to the Effective Date of this Judgment,
then such Attorney General shall notify Merck in writing of the specific
objection, identify with particularity the provisions of this Judgment that the
14

practice appears to violate, and give Merck thirty (30) days to respond to the
notification; provided, however, that a Signatory Attorney General may take
any action where the Signatory Attorney General concludes that, because of
the specific practice, a threat to the health or safety of the public requires
immediate action.
Upon receipt of written notice, Merck shall provide a good-faith written
response to the Attorney General notification, containing either a statement
explaining why Merck believes it is in compliance with the Judgment, or a
detailed explanation of how the alleged violation occurred and a statement
explaining how Merck intends to cure the alleged breach.
24.
Upon giving Merck thirty (30) days to respond to the notification
described above, the Signatoiy Attorney General shall also be permitted
reasonable access to inspect and copy relevant, non-privileged, non-work
product records and documents in the possession, custody or control of Merck
that relate to Merck’s compliance with each provision of this Judgment as to
which cause that is legally sufficient in the State has been shown. If the
Signatory Attorney General makes or requests copies of any documents during
the course of that inspection, the Signatory Attorney General will provide a list
of those documents to Merck. Nothing in this paragraph shall be interpreted to
limit the State’s Civil Investigative Demand (“CID”) or subpoena authority to the
extent such authority exists under applicable state law and Merck reserves all
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of its rights with respect to a CID or subpoena issued pursuant to such
authority
25.
The State may assert any claim that Merck has violated this Judgment in
a separate civil action to enforce this Judgment, or to seek any other relief
afforded by law, only after providing Merck an opportunity to respond to the
notification described in Paragraph 24 above; provided, however, that a
Signatory Attorney General may take any action where the Signatory Attorney
General concludes that, because of the specific practice, a threat to the health
or safety of the public requires immediate action.
26.
This Judgment represents the full and complete terms of the settlement
entered into by the parties hereto. In any action undertaken by either the
Attorneys General, or any of them, or Merck, no prior versions of this
Judgment, and no prior versions of any of its terms, that were not entered by
the Court in this Judgment, may be introduced for any purpose whatsoever.

IT IS SO STIPULATED
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DEFENDANT’S SIGNATURE AND
ACKNOWLEDGMENT

Defendant and its attorney have read and understand this Consent
Judgment and each of its terms. Defendant admits to the jurisdiction of the
Court in this matter and consents to the entry of this Consent Judgment.
Defendant agrees to each and every term contained herein.
I, Bruce Kuhlik, being first duly sworn on oath, depose and say that I am
an officer of Merck & Co., Inc., and am fully authorized and empowered to sign
this Consent Judgment on behalf of Merck & Co., Inc. and bind the same to
the terms hereof.

Bruce Kuhlik
Executive Vice President & General
Counsel
Merck & Co., Inc.

SUBSCRIBED and SWORN to before me on this ¡ 3

day of M /fK . 2008.

c -r r W il^
NOTARY PUBLIC ----- ^
My Commission Expires:

w

THERESA PISARCZYK
NOTARY PUBLIC OF NEW JERSEY
A

■ x

r

Approved as to form

WY COMMISSION EXPIRES MAR. 16. 2011

Nicholas M. Gess, ME Bar No. 002504
Bingham McCutchen LLP
2020 K Street, NW
Washington, DC 20006-1806
Counsel for Merck & Co., Inc.
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Accepted this

, 2008.

day of

G. STEVEN ROWE
Attorney General

DATED:

LinddrJ. Conti,
Assistant Attorney General
Maine Bar Registration No. 3638
Office of Attorney General
6 State House Station
Augusta ME 04333-0006
Tel: (207) 626-8591
Attorneys for Plaintiff, State of Maine

This Consent Judgment is hereby accepted for entiy of judgment for all
purposes set forth herein.
IT IS SO ADJUDGED AND ORDERED

Dated this

'XXX

day of
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M A IN E A T T O R N E Y G E N E R AL
M EM ORANDUM

TO:

Donna Heavener, Research Assistant

FROM :

Linda Conti, Chief, Consumer Protection Division

Cc:
bcc:

Laurie Simpson, Research Assistant
L. Conti

D ATE:

June 4, 2008

SUBJECT:

Deposit to Consumer & Antitrust Account and General Fund
State v. Merck & Co., Inc. CV-08-177

../

/7

A^

^ J

Attached is a check for $1,135,320.86 from Merck. This represents payment in accordance with
the attached consent judgment. Please have Maine Treasury deposit $1,100,000 o f the check
into the General Fund and the remaining $35,320.86 into the Consumer and Antitrust

Account.
Thanks.

OFFICE OF ATTORNEY
GENERAL

Consumer Protection Division
6 State House Station
Augusta, Maine 04333-0006

Phone: 626-8 543
FAX: 626-8812

Memorandum
To:
From:
CC:
Date
Subject:

Laurie Simpson
Linda Conti
Steve Rowe
June 4, 2008
Merck & Co.

Laurie, attached please find a check from the Merck & Co. Consent
Judgment in the amount of $1,135,320.86. Please deposit
$1,100,000.00 in the General Fund.
Please deposit the remaining $35,320.86 in the Consumer and
Anit-trust account.
Thanks for your attention to this matter.

Office of Counsel

Merck & Co., Inc.
P.0. Box 1000

North Wales PA 19454-1099

O

MERCK

June 2, 2008

Via UPS Overnight Delivery
Linda Conti
Assistant Attorney General
State o f Maine, Attorney General
6 SHS
Augusta, M E 04333

RE:

Merck & Co., Inc. Consent Judgment

Dear Ms. Conti:
Enclosed please find a check in the amount o f $1,135,320.86 in satisfaction o f Merck
& Co., Inc.'s payment obligation under the Consent Judgment. I f you have any questions
regarding this payment, please contact me at 267-305-5465.

V'

J~“1-------

Timothy K. Howard
Assistant Counsel

TKH:dm
Enel.

CONSUMER PROTECTION DIVISION

RECEIVED
JUN 0 3 2008
OFFICE OF ATTORNEY GENERAL

MERCK

O

CHECK DATE:
NO. C091 12681

(908) 236-3000

Merck & Co„ Inc.

PURCHASE
ORDER NO.

DATE

INVOICE NO.

GROSS AMOUNT

32981469 PJ

ADJUSTMENTS

1

NET AMOUNT

GROSS AMOUNT

DOCUMENT

05/27/08

52708ME

05/30/08
PAGE 1 OF

1,135,320.86

1,135,320.86

NET AMOUNT

DISCOUNT

TOTALS

o

PAYEE NO.

50-937

G09112681

(908) 236-3000

MERCK

$1,135,320.86

0.00

0.00

$1,135,320.86

CHECK DATE

213

AMOUNT

PAY;.,.

Merck &Co., Inc.

5800100

05/30/08

***$1,135,320.86

One million one hundred thirty five thousand three hundred twenty and 86/100 Dollars

***$1,135,320.86
JPMORGAN CHASE BANK
Sy r a c u s e , n e w y o r k

OPERATING ACCOUNT
: TO THE
: ORDER OF

s

STA TE O F M AINE ATTORNEY GENERAL
L IN D A C O N T I A S S T A TTY GENERAL

AUTHORIZED SIGNATURE

/A

AUGUSTA ME 0 4 3 3 3 U N IT E D
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¿27=
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AUTHORIZED SIGNATURE

STATES

SECOND SIGNATURE REQUIRED
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